Introduction
Ionizing radiation (IR) and cytoreductive drugs, such as cyclophosphamide, adriamycin, etoposide and paclitaxil, are widely used to destroy neoplastic tissues. They initiate reactive oxygen species that may account for much of their lytic properties. Thus, the desired effects of these therapies may be offset by undesirable inflammatory reactions that limit therapy in humans. The majority of these agents adversely affect host hematopoietic and lymphoid tissues resulting in anemia, thrombocytopenia, leukopenia and suppression of the immune response. To offset some of the undesirable effects, dietary supplements and antioxidants have been increasingly utilized. [1] [2] [3] [4] [5] [6] They are presumed to reduce the toxic effects of the therapy, reduce oxidative stress and enhance the host immune response to some cancers. Some have antitumor activity and others may enhance the effect of other anticancer treatments. 3, 5, 6 Despite a great number of reported studies, an excellent review by Malmberg 5 and a meta-analysis by Block et al. 6 point out that their ability to enhance tumor killing is variable and that the loss of host immune response to tumor antigens is a potential drawback. In this regard, there are very few agents that have proven clinically effective in reducing normal tissue injury induced by IR and cytoreductive chemotherapy. 7, 8 Of these, the aminothiol pro-drug amifostine is a free radical scavenger and is clinically effective in reducing IR and chemotherapy-induced injury to normal tissues without apparently compromising their antitumor properties. [2] [3] [4] In autologous transplantation, it has allowed higher doses of radiation by reducing toxicities such as mucositis. Because destruction of the oral mucosa reduces the barrier to infection, reduction in mucositis is an important advantage.
Our own experimental work and data from the literature [9] [10] [11] [12] led us to propose that the milieu created by conditioning played a very major role in the development of acute graft-versus-host disease (aGVHD). We reasoned that the administration of antioxidants that could inhibit IR induction of inflammatory cytokines and/or inhibit IR-induced apoptosis could have a beneficial effect on the initiation of aGVHD. In addition to amifostine, our choices of other likely candidates were the thiol-containing antioxidants n-acetyl cysteine (NAC) and pyrrolidine dithiocarbamate (PDTC), both of which inhibit nuclear factor-kB activation and nuclear translocation and thereby the transcription of many cytokines, chemokines and adhesion molecules. 13, 14 We 9,10 and others 11, 12 have demonstrated the critical role of tumor necrosis factor a and interleukin-1b in pathogenesis of aGVHD. We tested their administration prior to lethal total body irradiation (TBI) and allogeneic bone marrow (BM)/spleen transplantation in our standard protocol that typically leads to fatal aGVHD. In this study, we report that treatment with 400 mg/kg amifostine 30 min before 8.5 Gy lethal TBI of BALB/c H2 d mice and transplantation with fully allogeneic H2 b C57Bl/6 BM and spleen cells (SCs) preserved the ability of the host immune system to reject the allotransplant within 7 days. On the contrary, neither PDTC nor NAC prevented allogeneic engraftment and the animals died from toxicity and/or aGVHD.
Methods

Cell preparation
To obtain the necessary SCs, 8-to 12-week-old C57Bl/6 (B6) mice were euthanized with CO 2 asphyxiation followed by cervical dislocation. Whole spleens were washed with phosphate-buffered saline (PBS), placed in RPMI (Gibco, Grand Island, NY, USA) containing 10% fetal calf serum (Hyclone, Logan, UT, USA), penicillin-streptomycin and L-glutamine (Invitrogen, Carlsbad, CA, USA) and processed in a Stomacher Biomaster (Sampling Solutions Ltd., Rugby, Warwickshire, UK). The cell suspension was removed from the processing bag and passed through a nylon mesh filter. BM was obtained by aspiration from the femur and tibia of the same animals, dispersed though a steel sieve and centrifuged to remove fat globules. Mononuclear cells were separated on a Ficoll-Hypaque gradient (Sigma-Aldrich Inc., St Louis, MO, USA). Interface cells were removed and washed twice with complete media. The cells were resuspended at the desired concentration and aliquoted into tubes for treatment.
Radiation
Radiation was performed with a Mark IV 137 Cesium irradiator (JL Shepard, Glendale, CA, USA) at a dose rate of 2.0 Gy min
À1
. TBI (8.5 Gy) was administered in vivo and the doses are listed in the in vitro experiments.
Transplant model
Transplantation of fully allogeneic BM þ SCs from C57Bl/6 (B6) H2 b donors into lethally radiated BALB/c H2 d hosts consistently results in aGVHD. 9, 10 Depending on the number of T-cell-containing SCs added to the standard 10 Â 10 6 BM inoculum, we can manipulate the outcome from 100% fatal in 7-10 days to a more lingering yet fatal outcome or to a milder form from which most of the animals will recover. The addition of 2.5 Â 10 6 or more Tcell-containing donor SCs results in generally fatal aGVHD within 9-17 days. Unless otherwise specifically stated groups of 8-to 10-week-old BALB/c mice received 8.5 Gy TBI followed within 1 h by the intravenous (i.v.) injection of 10 Â 10 6 allogeneic B6 BM cells þ 2.5 Â 10 6 spleen SCs from the same donors. The animals were observed daily for signs of diarrhea, hunched posture, ruffled fur, skin lesions and decreased activity, and weighed three times weekly. According to association for assessment and accredition of animal laboratory care (AAALAC) and local guidelines, animals that lost more than 2 g of body weight in 48 h, developed severe diarrhea or became too lethargic to eat or drink were euthanized and counted as a death.
Thiol compounds
Amifostine, NAC and PDTC were purchased from SigmaAldrich Inc.; WR-1065 was purchased from Ash Stevens Inc., Detroit, MI, USA.
Phenotypic analysis
The viability, H2 d (host) and H2 b (donor) phenotypes and absolute numbers of CD3 þ T cells were compared in the amifostine-treated and transplanted versus the non-amifostine-treated and transplanted recipients. The spleens were obtained from groups of animals killed on day 7 (before the signs of aGVHD usually begin), from the survivors on day 14 and from the long-term amifostine-treated survivors on days 36 and 61. After isolating and washing the cells at 10 1C, they were resuspended in 5 ml cold flow cytometry medium containing 0.5% bovine serum albumin þ 0.02% azide in PBS, pH 7.4, counted with crystal violet (5%) þ acetic acid (0.0125%) and resuspended in flow cytometry medium at 20 Â 10 6 cells/ml. To prevent Fc binding, the cells were blocked with CD16/32 (clone MFCR00) for 5 min, following which they were incubated with antibodies purchased from Caltag (Carlsbad, CA, USA) unless otherwise noted: anti-H2K b (AFG-885) and -H2K
d (34-2-12) ; and isotype controls: hamster immunoglobulin (Ig) G (HM01); rat Ig (R2a01, R2a04); rat IgG2b (R2b20, R2b04). After incubation for 15 min on ice, the cells were washed twice in cold wash buffer (0.01% azide in PBS), following which 0.2-0.3 ml 1% paraformaldehyde (in PBS pH 7.4) was added and submitted for flow cytometry. Glutathione disulfide ratio as a measure of cellular redox Normal mouse SCs (NMSCs) were harvested in PBS 1 h after the indicated treatments. Each sample was split into two separate 500 ml aliquots, one for the determination of total non-protein-bound glutathione and glutathione disulfide (GSH þ GSSG) and the second for the determination of oxidized GSSG. 15, 16 For the determination of GSSG, the samples were supplemented with N-ethylmaleimide (3.8 mM) to alkylate-free thiol groups. Proteins were precipitated with 100 ml cold 18% perchloric acid. Supernatants (150 ml) were neutralized with 100 ml 1M KP 1 (pH ¼ 7.0) and reduced with 10.4 mM dithiotreitol for 60 min at room temperature. GSH was derivatized in the presence of 11.2 mM o-phthalaldehyde and separated by reverse-phase high-performance liquid chromatography set to an excitation wavelength of 340 nm and an emission wavelength of 420 nm. The sample was separated isocratically on Brownlee columns with propionate buffer (in 35 nM NaP i pH ¼ 6.5)/acetonitrite at a flow rate of 1.2 ml/min. Levels of reduced GSH were calculated as the difference between GSH þ GSSG and GSSG. The cellular GSH redox state is expressed as the GSH/GSSG ratio. Three samples were taken from each culture, each performed in triplicate and subjected to the above methods. The mean and s.d. of the three samples was calculated for GSH, GSSG and for the GSH/GSSG ratio for each of the experimental treatments.
Quantitation of hydrogen peroxide
After incubation with the various compounds, the cells were pelleted via centrifugation and supernatants were assayed by the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Molecular Probes, Eugene, OR, USA). The assay was performed according to the manufacturer's instructions. The results were determined from standards of known concentration assayed alongside the experimental samples.
Mitogen response
Lymphocytes were isolated from BALB/c mice dispersed SCs isolated by centrifugation over Ficoll-Hypaque lymphocyte separation medium (LSM-Mediatec 25-072-CV). The lymphocyte layer was carefully removed and the cells were washed in PBS. The cells were adjusted to 1 Â 10 6 per well and added in triplicate to 96-well trays. Some wells were left otherwise untreated. Others were pretreated with either 100 mM amifostine or 100 mM WR-1065. Phytohemaglutinin (PHA) (5 mg/ml; Sigma-Aldrich) was added to each well and followed by 0, 4, 8 or 10 Gy IR. The cells were cultured for 1-6 days. At 18 h prior to harvest, 10 ml of 0.2 mCi/ml 3 H-thymidine was added. The cells were harvested into a Titertek Multiple Cell Harvester, the filters were dried, added to scintillation vials containing 1 ml OPTI-FLUOR (PerkinElmer Inc., Waltham, MA, USA) and the disintegrations per minute counted.
Statistics
For the survival data, the data were analyzed by log rank statistics. The P-values reflect the difference between the survival curves. For the other data, two-tailed t-test statistics assuming unequal samples were performed. The data are expressed as means ± s.d. that is reflected as error bars above the data bars. Po0.05 was taken as statistically significant.
Results
Amifostine prevents engraftment of allogeneic BM SCs avoiding aGVHD At 30 min following 8.5 Gy TBI, 8-to 10-week-old BALB/c mice were transplanted i.v. with 10 Â 10 6 BM þ 2.5 Â 10 6
SCs isolated from 8-to 10-week-old C57Bl/6 (B6) mice. The mice were observed daily and weighed three times weekly. Since there was no change in the body weight or appearance of the amifostine-treated animals while most of the NAC, PDTC or PBS animals had died, the experiments were terminated at 21 days. Previous experiments had established that BALB/c mice that received 400 mg/kg amifostine followed by 8.5 Gy TBI alone survived for the duration of the 30-day experiment. Therefore, for comparison, in the first experiment the mice were pretreated intraperitoneally (i.p.) with the molar concentrations of NAC and PDTC equal to that of amifostine, that is, 400 mg/kg amifostine (1.8 mM/kg) ¼ 304 mg/kg NAC and 307 mg/kg PDTC. Four of the five PDTC-treated mice died within a few hours after TBI ( Figure 1a) . None of the amifostine-pretreated mice developed weight loss or other signs of aGVHD and all survived for 21 days. The NAC mice all rapidly lost weight and died probably as a result of the high toxic 304 mg/kg dose. Although two of the control PBS animals survived 21 days, they lost weight and exhibited other signs of aGVHD. Amifostine survival versus NAC (P ¼ 0.0018); versus PDTC (P ¼ 0.0025); versus PBS (P ¼ 0.0126).
Since the doses of PDTC and perhaps NAC were toxic, we repeated the experiment comparing survival of 400 mg/ kg amifostine with 100 mg/kg PDTC, 100 mg/kg NAC or PBS i.p. After 30 min, they received 8. Groups of normal BALB/c 8-to 10-week-old mice were injected intraperitoneally (i.p.) with either pyrrolidine dithiocarbamate (PDTC), amifostine (AMI), n-acetyl cysteine (NAC) or phosphate-buffered saline (PBS). After 30 min, they received 8.5 Gy total body irradiation (TBI) and were transplanted intravenously (i.v.) with 10 Â 10 6 BM þ 2.5 Â 10 6 SCs isolated from 8-to 10-week-old H2-incompatible C57Bl/6 (B6) mice. Experiment 1 compares the survival of transplanted mice that had been pre-treated with 400 mg/kg amifostine pre-treatment with that of molar equivalent doses of NAC and PDTC. Experiment 2 compares the survival of another group of transplanted mice pre-treated with 400 mg/kg amifostine with that of non-toxic doses of NAC and PDTC. and all lived for the 21 days of this experiment. The NACtreated mice rapidly lost weight and developed signs of aGVHD and all died by day 16. Although less pronounced early in the experiment, the PDTC-and PBS-pretreated animals also developed aGVHD. One control PBS pretreated animal survived for 21 days but none of the PDTCand NAC-treated mice survived. Amifostine survival versus NAC (P ¼ 0.0018); versus PDTC (P ¼ 0.0016); versus PBS (P ¼ 0.0495).
There were several possible explanations for this rather surprising result. One was that amifostine had inhibited donor T-cell antihost activation. Another was that allorecognition had occurred but the inflammatory reaction was prevented. However, based on the observation that the amifostine-treated mice exhibited no signs of aGVHD, the possibility also existed that the amifostine had so altered the effect of TBI that host BALB/c-immunocompetent cells survived the radiation and rejected the donor cells. Therefore, two additional experiments were performed. A total of 47 BALB/c mice received 8. (Table 1) . Additionally, the ratio of spleen weight to body weight has been shown to be a good indication of aGVHD (Simonsen Index); higher ratios correlate with aGVHD. The mice were weighed daily and inspected for signs of aGVHD. If an animal lost more than 2.0 g body weight within 48 h, the animal was euthanized and counted as an experimental death. None of the amifostinetreated mice lost significant weight and all appeared healthy at the time of euthanasia for cytometric analysis. Of the 29 amifostine-treated mice, 9 were euthanized on day 7, 9 on day 14, 5 on day 36 and 6 on day 61. Whereas more than 98% of the SCs in 8/9 of the amifostine-treated mice examined on day 7 were recipient H2 d positive, one animal was partially engrafted with 27.3% donor H2 b cells. On day 14, more than 97% of the SCs in 7/9 mice were recipient H2 In contrast, control mice that received a similar volume of PBS developed severe aGVHD. Daily weights confirmed marked weight loss in the PBS controls. Eleven of these animals were euthanized on day 7. The ratio of spleen weight divided by body weight (Simonsen Index) for this group was 4.9 as compared to 1.9 in the amifostine-treated mice, supporting the diagnosis of aGVHD. By day 14, only two of the PBS-treated mice were still alive for testing. The percentage of H2 b cells was 91.5%, indicating that there had not been complete donor engraftment in the two mice that survived to this day. However, the Simonsen Index was elevated at 4.3, again reflecting the occurrence of aGVHD.
Taken together, this data demonstrate that the amifostine-treated hosts rejected the allogeneic transplant and did not develop aGVHD. In contrast, the mice that received only PBS were populated with allogeneic H2 b donor cells and developed aGVHD. Although it was anticipated that amifostine would prevent some of the effects of lethal IR, the degree was unexpected. Not only did the mice survive, suggesting multi-lineage recovery, but they also did not lose significant weight, suggesting that the bowel was protected. The rapidity and completeness of the rejection of the allogeneic transplant also suggested that amifostine might actually have accelerated the host immune response to the allograft. In contrast, molar equivalent doses of NAC and PDTC were toxic and lower doses did not prevent aGVHD.
In vitro tests with NMSCs demonstrate that NAC and PDTC act as pro-oxidants in contrast to amifostine and WR-1065
The obvious question was why did these three thiolcontaining compounds have such profoundly different effects on engraftment of allogeneic cells and thus on the development of aGVHD? We reasoned that at least one explanation might relate to their acting as pro-or antioxidants. Therefore, NMSCs were incubated in vitro with amifostine, WR-1065, NAC and PDTC to determine their effects on the GSH level, on the GSH/GSSG ratio and on the release of H 2 O 2 as indicators of oxidant stress.
PDTC acts as a pro-oxidant when added to NMSC First, we determined the effect of these four drugs on the level of GSH and the GSH/reduced GSSG ratio. NMSCs were incubated for 1 h with doses of 0.0, 1.0 and 10.0 mM amifostine, WR-1065, PDTC and NAC. The data are presented as a percentage change compared to that in the untreated but similarly cultured PBS control. PDTC lowered GSH and the GSH/GSSG ratio (Po0.001) (induced thiol oxidation). Although both NAC and WR-1065 tended to increase GSH above the PBS-treated control, the increases did not quite reach statistical significance (Figure 2a) . However, both 1.0 mM (Po0.01) and 10.0 mM (Po0.01) WR-1065 significantly increased the GSH/GSSG ratio, reflecting a protective effect on the intracellular environment (Figure 2b ).
NAC to a greater degree than PDTC or amifostine stimulates H202 from NMSC Using the Amplex Red assay, we directly measured the release of H 2 O 2 from NMSC cultures treated for 2 h with 0.0, 0.1, 0.5, 1.0 and 10.0 mM NAC, amifostine and its active metabolite WR-1065 (Figure 3 ). Whereas 10.0 mM PDTC, 1.0 and 10 mM NAC and 10.0 mM amifostine significantly increased H 2 O 2 release above control, WR-1065 did not. The greatest increase was by 1.0 and 10.0 mM NAC as compared to the increases by PDTC and amifostine. Doses less than 1.0 mM had no effect.
Amifostine and WR-1065 prior to IR reduce/prevent radiation-induced loss of the response of NML to respond to PHA As documented in Table 1 , there were few to zero detectable H2 b donor cells in the spleens of the amifostine-pretreated BALB/c mice transplanted with H2 b C57Bl/ 6 BM and SC at 7 and 14 days and none on days 36 and 61. This suggested that amifostine had prevented TBI-induced destruction of BALB/c host immune function. To test this hypothesis, we examined the effect of amifostine and its active metabolite WR-1065 to either prevent or reduce radiation-induced suppression of the response of isolated normal mouse BALB/c lymphocytes (NMLs) to PHA ( Figure 4 ). This is relevant because T-cell recognition and activation are essential for the rejection of allogeneic tissues. If amifostine could prevent radiation-induced killing of normal lymphocytes in vitro at doses similar to that used in transplantation, then this would strongly support this hypothesis. Lymphocytes were isolated from 10 mice; 5 Â 10 6 /ml were placed in 96-well U-bottom plates following which 100 mM amifostine or WR-1065 or control PBS was added. The cells were then radiated with 0, 4, 8 or 10 Gy IR followed by the addition of 5.0 mg/ml PHA in 30 min. The cells were cultured for 2, 3, 4, 5 or 6 days and 16 h prior to harvest, 1.0 mCi Cell proliferation measured in disintegrations per minute was compared daily between the amifostine-and WR-1065-treated and control PBS-treated cultures. Figure 4 demonstrates that amifostine and WR-1065 protected the lymphocytes from 4, 8 and even 10 Gy IR, preserving their response to PHA.
Amifostine and WR-1065 prolong the response to PHA and stimulate 3 H incorporation de novo This protection raised the question whether amifostine and WR-1065 only protect cells when they are administered before an oxidant stress or could they actually serve to promote lymphoid growth in the absence of agents causing oxidant stress and cell death? Could they actually heighten the normal immune response? Amifostine (100 mM), WR-1965 (100 mM) or control PBS was added to NML cultures. PHA (5 mg/ml) was added to one-half of the cultures. They were incubated for 1, 2, 4, 5 or 6 days. As above, 16 h prior to harvest 1 mCi 3 H-thymidine (ICN Biomedical) was added. They were harvested in triplicate and the b emissions were counted. Whereas the response to 5 mg/ml PHA alone peaked at day 4, it remained elevated to at least day 6 in the cultures treated with either amifostine or WR-1065 ( Figure 5 ). Furthermore, WR-1065 alone significantly stimulated 3 H incorporation into untreated NML culture for 2 days and both amifostine and WR-1065 alone significantly stimulated incorporation into cells cultured for 4 days (Figure 6 ). This pattern is similar to the response of NML to PHA alone ( Figure 5 ), suggesting that WR-1065 and perhaps amifostine were acting as mitogens to induce DNA synthesis.
Discussion
It is now well established that amifostine protects normal cells from IR 17 and chemotherapy-induced injury. 18 In contrast, it does not generally appear to protect tumor cells from the effects of these agents. 8, 18 Thus, its potential therapeutic index can be of benefit in the treatment of many cancers. This protection seems to include a variety of normal cells including lymphocytes. 19 Whereas it is clear that amifostine facilitates early recovery of hematological and lymphoid cells following autologous transplantation, some chemotherapy 20 and more localized radiotherapy for cancer therapy, 21, 22 its effect on recovery of these tissues in allogeneic stem cell transplantation (allo-SCT) has not been as well documented. 23 Of concern is the possibility that the very same ability to protect lymphocytes may have negative consequences when the intent of treatment is to cause immunosuppression. For example, its use in transplantation of either allogeneic stem cells or in association with immunosuppressive treatment for solid organ transplantation could be to prevent or inhibit the destruction of normal lymphocytes and thereby preserve the immune system in unwanted situations. The effect of concomitant amifostine administration may be to reduce the effectiveness of these drugs. Not only did amifostine and WR-1065 prevent radiation-induced inhibition of the NMSC's response to PHA, it prolonged their response to PHA on day 5 (data not shown) and day 6 in the absence of IR. Furthermore, they actually enhanced the NML growth in culture in the absence of either PHA or IR ( Figure 6 ). The capacity of amifostine to stimulate BM colony forming units granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM) and burst forming unitserythroid (BFU-E) cell growth has been observed in murine cells after radiation 18 and normal non-irradiated human marrow, 24 but to our knowledge has not heretofore been noted with lymphoid cells.
Does this apply to other agents that could reduce the toxicity of IR or chemotherapy? The data presented herein document that another clinically used antioxidant NAC did not prevent allogeneic stem cell engraftment nor did it prevent aGVHD. What distinguishes amifostine from NAC and PDTC? We hypothesize that the observed benefit of amifostine on the immune system could be the result of several factors: first, its free radical scavenging function could eliminate the majority of the initial TBI-induced burst of free radicals; second, amifostine induced generation of MnSOD to protect against second-generation free radicals and third, arrest of the cell cycle until DNA repair and replication can occur. As noted above, both NAC and PDTC are excellent free radical scavengers but they did not preserve the host's ability to reject the allogeneic graft. NAC has been used to treat steroid resistant aGVHD following BM transplantation 7 and acetaminophen toxicity. 25 Yet under other experimental conditions, NAC and PDTC stimulated apoptosis in vascular smooth muscle cells. 26 PDTC is another effective free radical scavenger. In vivo, PDTC protected mice from endotoxin and tumor necrosis factor a-induced lethal shock, 27, 28 rabbits from staphylococcal enterotoxin A-induced fever 29 and cold perfusion-induced injury to orthotopic rat liver transplants. 30 In vitro, it has been reported to reduce the effect of ultraviolet radiation in experiments with cultured cell lines. 31, 32 On the other hand, under other experimental conditions PDTC has acted as a pro-oxidant. 33, 34 Given the clear distinction in the in vivo transplant experiments and conflicting in vitro reports in the literature, we chose two in vitro tests to compare the effects of amifostine and its active metabolite WR-1065 with NAC and PDTC. The first was to determine the level of GSH and the GSH/GSSG ratio as a measure of intracellular redox because these assays have been reported to distinguish NAC from PDTC. Whereas NAC protected mice from endotoxemia by regulating intracellular redox, 35 the pro-oxidant effect of PDTC was demonstrated by increasing the generation of GSSG. 16 Our data again document that PDTC acts as a pro-oxidant when incubated in vitro with NMSC by decreasing GSH and the GSSG ratio in contrast to NAC, amifostine and WR-1065. In another study, we have demonstrated that when PDTC precedes IR in vitro, it enhanced IR-induced cell death of NMSC (submitted for publication). This may help to explain why the higher dose of PDTC accelerated death after TBI and transplantation prior to the time when engraftment could occur and aGVHD develop.
The second test was to measure the effect of these agents to stimulate the oxidant H 2 O 2 . NAC along with PDTC significantly stimulated the release of H 2 O 2 , indicating that it also could act as a pro-oxidant when incubated with NMSC. In contrast, neither amifostine nor WR-1065 decreased GSH and the GSH/GSSG ratio or significantly stimulated H 2 O 2 , providing at least one explanation for their observed in vivo effects.
However, their use in allogeneic stem cell or solid organ transplantation to reduce toxicity should take into account that preservation of the immune system could prevent engraftment and/or allow solid organ rejection. Alternatively, there remains considerable controversy as to whether antioxidants may also reduce the tumoricidal effects of chemotherapy that act as strong oxidants. 5, 6 In this regard, Weiss et al. 36 have recently reported that NAC administered for 10 days after allo-SCT to BALB/c mice led to a mild reduction in graft-versus-leukemia.
Our data provide a clear example of the ability of amifostine to preserve T-lymphocyte function following lethal TBI and thereby cause the rejection of normal allogeneic BM supplemented with lymphocyte-containing SCs. The ability of pretreatment with amifostine and WR-1065 to preserve lymphocyte function in vivo was supported by the observation that amifostine preserved the response of isolated radiated normal lymphocytes to respond to PHA. Furthermore, they stimulated growth of nonradiated non-PHA-treated normal lymphocytes over the 6 days of culture.
Taken together, this in vivo and in vitro data herald a cautionary note when the use of amifostine is considered to reduce the toxicities of radiation or chemotherapy employed in conditioning allogeneic stem cell transplants or to prevent solid organ allogeneic graft rejection. To our knowledge, only one randomized trial of 30 patients has been reported for its use in allogeneic transplantation.
